Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9343626 | 0.95 | ALDH1A1 (0.42) | ALDH1A1USP2TSHRKDM4ELMNA | |
| SCHEMBL1710506 | 0.86 | CA2 (0.55) | ALDH1A1USP2TSHRKDM4ELMNA | |
| SCHEMBL1710503 | 0.86 | CA2 (0.55) | ALDH1A1USP2TSHRKDM4ELMNA | |
| SCHEMBL1710465 | 0.83 | CYP3A4 (0.53) | ALDH1A1USP2TSHRKDM4ELMNA | |
| SCHEMBL1710462 | 0.83 | CYP3A4 (0.53) | ALDH1A1USP2TSHRKDM4ELMNA | |
| SCHEMBL8343913 | 0.81 | CA1 (0.43) | CA1CA2CA12CA7CA14 | |
| SCHEMBL28142509 | 0.81 | CYP3A4 (0.47) | ALDH1A1USP2TSHRKDM4ELMNA | |
| SCHEMBL22638004 | 0.81 | CA12 (0.33) | ALDH1A1USP2TSHRKDM4ELMNA | |
| SCHEMBL13890120 | 0.81 | TSHR (0.52) | ALDH1A1USP2TSHRKDM4ELMNA | |
| SCHEMBL10151688 | 0.80 | CA1 (0.59) | ALDH1A1USP2TSHRKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-11718631-B2 | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-08-08 | — | — | US | disclosed |
| US-11702428-B2 | Chemical compounds as inhibitors of interleukin-1 activity | GENENTECH, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
| US-11446261-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210077427-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2021-03-18 | — | — | US | disclosed |
| US-10639286-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190183816-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2019-06-20 | — | — | US | disclosed |
| US-20090253927-A1 | PROCESS FOR CYCLOHEXANECARBOXYLIC ACID DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-10-08 | — | — | US | disclosed |
| US-20090253928-A1 | PREPARATION FOR A CYCLOHEXANECARBOXYLIC ACID DERIVATIVE AND INTERMEDIATES | HOFFMANN-LA ROCHE, INC. | 2009-10-08 | — | — | US | disclosed |
| WO-2009121788-A1 | NEW PROCESS FOR THE PREPARATIION OF CYCLOHEXANECARBOXYLIC ACID DERICATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-08 | — | — | WO | disclosed |
| US-20090240080-A1 | PROCESS FOR THE PREPARATION OF CETP(1) | HOFFMANN URSULA | 2009-09-24 | — | — | US | disclosed |
| EP-2094636-A1 | PROCESS FOR PREPARING 1-(2-ETHYL-BUTYL)-CYCLOHEXANECARBOXYLIC ACID | F. Hoffmann-Roche AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| EP-2091955-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | Acucela, Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| WO-2009045479-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| US-20080154059-A1 | PROCESS FOR THE PREPARATION OF CETP(1) | HOFFMANN-LA ROCHE INC. | 2008-06-26 | — | — | US | disclosed |
| WO-2008074677-A1 | PROCESS FOR PREPARING 1- (2-ETHYL-BUTYL) -CYCLOHEXANECARBOXYLIC ACID | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| EP-1935867-A1 | Process for preparing 1-(2-ethyl-butyl)-cyclohexanecarboxylic acid | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | ALDH1A1 140/4885USP2 3553/4885TSHR 2964/4885 |
| US-20080154059-A1 | PROCESS FOR THE PREPARATION OF CETP(1) | CETP, CES1, CPA1 | ALDH1A1 1871/4885USP2 1810/4885TSHR 4374/4885 |
| US-20090240080-A1 | PROCESS FOR THE PREPARATION OF CETP(1) | CETP, CES1, CPA1 | ALDH1A1 1871/4885USP2 1810/4885TSHR 4374/4885 |
| US-20210077427-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | ALDH1A1 140/4885USP2 3553/4885TSHR 2964/4885 |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | ALDH1A1 133/4885USP2 3473/4885TSHR 2971/4885 |
| US-20190183816-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | ALDH1A1 140/4885USP2 3553/4885TSHR 2964/4885 |
| US-11718631-B2 | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | ALDH1A1 1237/4885USP2 3047/4885TSHR 4555/4885 |
| US-20090253927-A1 | PROCESS FOR CYCLOHEXANECARBOXYLIC ACID DERIVATIVES | CYP2C9, CYP51A1, CYP2B6 | ALDH1A1 166/4885USP2 3239/4885TSHR 3920/4885 |
| US-11446261-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | ALDH1A1 140/4885USP2 3553/4885TSHR 2964/4885 |
| US-11702428-B2 | Chemical compounds as inhibitors of interleukin-1 activity | IL1B, IL1A, IL18 | ALDH1A1 649/4885USP2 2310/4885TSHR 2419/4885 |
| US-20090253928-A1 | PREPARATION FOR A CYCLOHEXANECARBOXYLIC ACID DERIVATIVE AND INTERMEDIATES | CYP2A13, CYP1A1, CYP2C19 | ALDH1A1 114/4885USP2 3059/4885TSHR 3952/4885 |
| US-10639286-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | ALDH1A1 140/4885USP2 3553/4885TSHR 2964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.